ABSTRACT
Background Soluble tumor necrosis factor receptor (sTNFR)1, sTNFR2, and plasma kidney injury molecule-1 (KIM-1) are associated with kidney events in patients with and without diabetes. However, their associations with clinical outcomes when obtained pre-operatively have not been explored.
Methods The TRIBE-AKI cohort study is a prospective, multicenter, cohort study of high-risk adults undergoing cardiac surgery. We assessed the associations between pre-operative concentrations of plasma sTNFR1, sTNFR2, and KIM-1 and post-operative long-term outcomes including mortality, cardiovascular events, and chronic kidney disease (CKD) incidence or progression, ascertained after discharge.
Results Among 1378 participants included in the analysis with a median follow-up period was 6.7 (IQR 4.0-7.9), 434 (31%) patients died, 256 (19%) experienced cardiovascular events and out of 837 with available long-term kidney function data, 30% developed CKD. After adjustment for clinical covariates, each log increase in biomarker concentration was independently associated with mortality with 95%CI adjusted hazard ratios (aHRs) of 3.0 (2.3-4.0), 2.3 (1.8-2.9) and 2.0 (CI 1.6-2.4) for sTNFR1, sTNFR2 and KIM-1, respectively. For cardiovascular events, the 95%CI aHRs were 2.1 (1.5 – 3.1), 1.9 (1.4 – 2.6) and 1.6 (1.2 – 2.1) for sTNFR1, sTNFR2 and KIM-1, respectively. For CKD events, the aHRs were 2.2 (1.5 – 3.1) for sTNFR1, 1.9 (1.3 – 2.7) for sTNFR2, and 1.7 (1.3 – 2.3) for KIM-1. Despite the associations, each of the biomarkers alone or in combination failed to result in robust discrimination on an absolute basis or compared to a clinical model.
Conclusion sTNFR1, sTNFR2, and KIM-1 were independently associated with longitudinal outcomes after discharge from a cardiac surgery hospitalization including death, cardiovascular and CKD events when obtained pre-operatively in high-risk individuals. Pre-operative plasma biomarkers could serve to assist during the evaluation of patients in whom cardiac surgery is planned.
Competing Interest Statement
SGC has salary support from NIH grants R01DK115562 UO1DK106962 R01HL085757 R01DK112258 R01DK126477 and UH3DK114920. SGC reports personal income and equity and stock options from Renalytix and pulseData he also reports personal income from Axon Therapeutics Bayer Boehringer-Ingelheim CHF Solutions ProKidney Vifor and Takeda. EDS reports personal income from Akebia Therapeutics Da Vita and UpToDate he also serves as an associate editor for the Clinical Journal of the American Society of Nephrology. In the past 3 years SGC has received consulting fees from Goldfinch Bio CHF Solutions Quark Biopharma Janssen Pharmaceuticals Takeda Pharmaceuticals and Relypsa. DGM is supported by an NIH K23 grant (K23DK117065) and by the Yale O Brien Kidney Center (P30DK079310). SGM is supported by AHA (18CDA34110151) the Yale O Brien Kidney Center and the Patterson Trust Fund. NIH (R01HL085757 to CRP) funded the TRIBE-AKI Consortium. SGC and CRP are members of the advisory board of Renalytix AI and own equity in the same. JLK has received research fees from Bioporto and Astute Medical and consulting fees from Baxter Astute Medical and SphingoTec. All the other authors declared no competing interests.
Funding Statement
The research reported in this article was supported by the American Heart Association Clinical Development Award, as well as by the grant R01HL-085757 from the National Heart, Lung, and Blood Institute. C.R.P. is also supported by an NIH grant (K24DK090203). S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185). S.G.C. M.G.S, and C.R.P. are members and are supported in part by the Chronic Kidney Disease Biomarker Consortium (1U01DK106962-01). DGM is supported by K23DK117065. JLK is supported by R21DK113420. The study was also supported by CTSA Grant Number UL1 RR024139 from the National Center for Research Resources (NCRR). This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC); Dr. Amit Garg is supported by the Dr. Adam Linton Chair in Kidney Health Analytics; no other relationships or activities that could appear to have influenced the submitted work. S.G.C. and C.R.P. are on the Advisory Board of RenalytixAI, and both own equity in the same. S.G.C. has served as a consultant for AKI therapeutics for Quark Biopharma and CHF Solutions. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions, and statements expressed herein are those of the authors, and not necessarily those of CIHI. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Yale University gave ethical approval for this work Ethics committee/IRB of Western University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
